Falecalcitriol

Drug Profile

Falecalcitriol

Alternative Names: DSC 103; F6VD3; Flocalcitriol; Fulstan; Hexafluorocalcitriol; Hexafluorovitamin D3; Hornel; SM 8000; ST 630

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator University of Wisconsin-Madison
  • Developer Bertek Pharmaceuticals; Discovery Laboratories; Sumitomo Dainippon Pharma; Taisho Pharmaceutical
  • Class Calcium regulators; Dihydroxycholecalciferols
  • Mechanism of Action Calcitriol stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Marketed Hyperparathyroidism; Osteomalacia; Rickets
  • Discontinued Acne; Photodamage; Postmenopausal osteoporosis; Psoriasis

Most Recent Events

  • 19 Jun 2014 Dainippon Sumitomo Pharma is now called Sumitomo Dainippon Pharma
  • 07 Aug 2007 Discontinued - Phase-I for Acne in USA (Topical)
  • 07 Aug 2007 Discontinued - Phase-I for Photodamage in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top